Who are Artiva Biotherapeutics, Inc.'s main suppliers?

Artiva Biotherapeutics, Inc. (ARTV) key suppliers include: GC-CELL, BLACKBIRD-CLINICAL-INC, Fate Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/ARTV.

Who are Artiva Biotherapeutics, Inc.'s major customers?

Artiva Biotherapeutics, Inc. (ARTV) key customers include: GC-CELL, Allogene Therapeutics, Inc., Allogene Therapeutics, Inc., Autolus Therapeutics plc, Autolus Therapeutics plc and 20 more. View the full customer network at chainsifter.com/chain/ARTV.

What sector is Artiva Biotherapeutics, Inc. in?

Artiva Biotherapeutics, Inc. (ARTV) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Artiva Biotherapeutics, Inc. Supplier List (ARTV): 3 Verified Suppliers

3Suppliers

25Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Artiva Biotherapeutics, Inc. (ARTV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

31Total relationships

1Distinct source URLs

6High confidence

0.726Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Artiva Biotherapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GC-CELL	GC-CELL	90%	In August 2020, the Company entered into a Research and Service Agreement with GC Cell in which GC Cell is to provide mutually agreed research services in support of the research and development of o…
BLACKBIRD-CLINICAL-INC	BLACKBIRD-CLINICAL-INC	80%	Under the terms of the Blackbird Services Agreement, Blackbird provides consulting services in connection with the Company's clinical trials, including study strategy, clinical operations and patient…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE g…

Artiva Biotherapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
GC-CELL	GC-CELL	80%	Under the AB-205 Agreement, GC Cell agreed to reimburse the Company for direct costs incurred on behalf of GC Cell in accordance with the Development Plan under the AB-205 Agreement, provided that su…
ALLO	Allogene Therapeutics, Inc.	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
ALLO	Allogene Therapeutics, Inc.	72%	Reciprocal relationship from ALLO graph: Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our bus…
AUTL	Autolus Therapeutics plc	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
AUTL	Autolus Therapeutics plc	72%	Reciprocal relationship from AUTL graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from AUTL g…
CRBU	Caribou Biosciences, Inc.	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
CRBU	Caribou Biosciences, Inc.	72%	Reciprocal relationship from CRBU graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from CRBU g…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely…
IPSC	Century Therapeutics, Inc.	72%	Reciprocal relationship from IPSC graph: Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our bus…
IPSC	Century Therapeutics, Inc.	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
KYTX	Kyverna Therapeutics, Inc.	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
KYTX	Kyverna Therapeutics, Inc.	72%	Reciprocal relationship from KYTX graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from ARTV graph: uture environmental regulations may…
LYEL	Lyell Immunopharma, Inc.	72%	Reciprocal relationship from LYEL graph: Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our bus…
LYEL	Lyell Immunopharma, Inc.	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
REGN	Regeneron Pharmaceuticals, Inc.	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ARTV graph: uture environmental regulations may…
RNAC	Cartesian Therapeutics, Inc.	72%	uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations. Any contamination …
RNAC	Cartesian Therapeutics, Inc.	72%	Reciprocal relationship from RNAC graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from ARTV graph: uture environmental regulations may…
BLACKBIRD-CLINICAL-INC	BLACKBIRD-CLINICAL-INC	62%	ayable and accrued expenses in connection with the GC Cell License Agreements and Research Service Agreement. In September 2023, the Company and GC Cell amended the AB-201 Agreement (see Note 7). The…
BLACKWELL-PARTNERS-LLC	BLACKWELL-PARTNERS-LLC	62%	ayable and accrued expenses in connection with the GC Cell License Agreements and Research Service Agreement. In September 2023, the Company and GC Cell amended the AB-201 Agreement (see Note 7). The…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	or tax liabilities. We have not completed a Section 382 ownership change analysis. If ownership changes have occurred or occur in the future, the amount of remaining tax attribute carryforwards avail…
GC-CELL-CORPORATION	GC-CELL-CORPORATION	62%	commencement of our operations. We have never generated any revenue from product sales and do not expect to generate any revenues from product sales unless and until we successfully complete developm…
GREEN-CROSS-CELL-CORPORATION	GREEN-CROSS-CELL-CORPORATION	62%	d financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	ach of the three months ended March 31, 2026 and 2025. Changes included a $0.1 million increase in personnel-related costs, offset by a $0.1 million decrease in other operational and legal costs. Oth…
ORGANIZATION-ARTIVA-BIOTHERAPEUTICS-INC	ORGANIZATION-ARTIVA-BIOTHERAPEUTICS-INC	62%	resentation Organization Artiva Biotherapeutics, Inc. (the Company) was incorporated in the State of Delaware on February 14, 2019 . The Company is a biopharmaceutical company focused on developing o…

Artiva Biotherapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ARTV-DEBT	Debt stack $10.9M	90%	Market cache reports total debt of $10.9M.
ARTV-DEBT-7861	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

Artiva Biotherapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Artiva Biotherapeutics, Inc..

Artiva Biotherapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
ARTV-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 41 tracked holders.

Artiva Biotherapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
IPSC	Century Therapeutics, Inc.	100.00	1	['customer']
UPB	Upstream Bio, Inc.	100.00	2
TBPH	Theravance Biopharma, Inc.	100.00	2
IMTX	Immatics N.V.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	1	['spend']
ALLO	Allogene Therapeutics, Inc.	100.00	1	['customer']
AZN	AstraZeneca PLC	100.00	2
GILD	Gilead Sciences, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
FATE	Fate Therapeutics, Inc.	100.00	2	['customer', 'supplier']
CHRS	Coherus Oncology, Inc.	100.00	2
KLRS	Kalaris Therapeutics, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
CELU	Celularity Inc.	100.00	2
ACET	Adicet Bio, Inc.	100.00	2
BNTX	BioNTech SE	100.00	2
CLLS	Cellectis S.A.	100.00	2
MYGN	Myriad Genetics, Inc.	100.00	2

Artiva Biotherapeutics, Inc. Supply Chain